📋 Key Information Summary
- Renal tubular acidosis (RTA) encompasses Type 1 (distal), Type 2 (proximal), and Type 4 (hyperkalaemic) — all present with normal anion gap metabolic acidosis (NAGMA).
- Type 1 RTA involves impaired H⁺ secretion in the distal nephron; bicarbonate supplementation at 1–2 mmol/kg/day (sodium bicarbonate or Shohl's solution) is first-line therapy.
- Type 2 RTA involves impaired HCO₃⁻ reabsorption in the proximal tubule; higher bicarbonate doses (4–10 mmol/kg/day) are often required, and potassium supplementation is critical.
- Type 4 RTA results from aldosterone deficiency or resistance and is characterised by hyperkalaemia; treatment targets the underlying cause with fludrocortisone or sodium bicarbonate.
- Urine anion gap (UAG) and urine pH help distinguish RTA types: UAG positive with urine pH > 5.5 suggests Type 1; UAG positive with urine pH < 5.5 suggests Type 4; bicarbonaturia on bicarbonate loading suggests Type 2.
- Nephrocalcinosis and recurrent nephrolithiasis are hallmark complications of untreated Type 1 RTA.
- Hypokalaemia is a prominent feature of Type 1 and Type 2 RTA; hyperkalaemia distinguishes Type 4 RTA.
- Causes include autoimmune disease (Sjögren syndrome, SLE), medications (amphotericin B, topiramate, tenofovir), hereditary conditions, and chronic kidney disease.
- Obtain serum electrolytes, venous blood gas, serum calcium, phosphate, alkaline phosphatase, urine pH, and urine electrolytes as baseline investigations.
- Patients with persistent acidosis may develop osteomalacia in adults and rickets in paediatric patients; monitor bone health with DXA and serum alkaline phosphatase.
- Refer to nephrology for diagnostic uncertainty, refractory acidosis, progressive CKD, or suspected inherited RTA syndromes.
- Aboriginal and Torres Strait Islander peoples may have higher prevalence of chronic kidney disease with tubular dysfunction; culturally safe screening and remote-access pathways are essential.
Introduction & Australian Epidemiology
Renal tubular acidosis (RTA) is a heterogeneous group of disorders characterised by normal anion gap metabolic acidosis (NAGMA) resulting from defective renal acid excretion or bicarbonate reabsorption, in the setting of relatively preserved glomerular filtration rate (GFR). Unlike uraemic acidosis, RTA arises from primary tubular dysfunction and cannot be attributed to accumulated organic acids.
Three principal types are recognised: Type 1 (distal RTA), involving a defect in distal tubular H⁺ secretion; Type 2 (proximal RTA), involving impaired proximal HCO₃⁻ reabsorption; and Type 4 (hyperkalaemic RTA), due to aldosterone deficiency or tubular unresponsiveness. Type 3 RTA, a historical hybrid, is rarely used in modern classification.
In Australia, RTA is most commonly encountered secondary to autoimmune conditions such as Sjögren syndrome and systemic lupus erythematosus (SLE), chronic kidney disease, and nephrotoxic medications. Distal RTA has an estimated prevalence of approximately 1 in 10,000 in the general population, though secondary forms are far more common. Aboriginal and Torres Strait Islander peoples carry a disproportionate burden of CKD and its complications, including tubular dysfunction, with rates of kidney disease approximately 2–4 times higher than non-Indigenous Australians (AIHW, 2023).
This guideline provides a structured approach to the diagnosis and management of RTA in the Australian primary care and specialist setting, emphasising evidence-based therapies available under the Pharmaceutical Benefits Scheme (PBS).
Type 1 RTA (Distal) — H⁺ Secretion Defect
Type 1 (distal) RTA results from an inability of the α-intercalated cells of the distal collecting duct to secrete H⁺ into the tubular lumen. This leads to a failure to generate new bicarbonate and maintain systemic acid–base homeostasis, resulting in persistent metabolic acidosis with an inappropriately elevated urine pH (typically > 5.5 even during acidosis).
Aetiology
- Primary (hereditary): Autosomal dominant or recessive mutations in genes encoding the H⁺-ATPase (ATP6V0A4, ATP6V1B1) or the Cl⁻/HCO₃⁻ exchanger (SLC4A1/AE1). Childhood presentation is common in recessive forms; dominant forms may present in adulthood.
- Secondary: Sjögren syndrome (most common secondary cause in Australia), SLE, rheumatoid arthritis, hypergammaglobulinaemia, cryoglobulinaemia, post-renal transplant, medullary sponge kidney.
- Drug-induced: Amphotericin B, ifosfamide, lithium, toluene inhalation, topiramate, zonisamide.
Clinical Features
- NAGMA with serum HCO₃⁻ typically 12–20 mmol/L.
- Hypokalaemia (often severe, K⁺ < 3.0 mmol/L) — due to increased distal Na⁺ delivery and aldosterone response.
- Nephrocalcinosis and nephrolithiasis (calcium phosphate stones) — present in ~70% of hereditary and ~20–30% of secondary cases.
- Osteomalacia (adults) or rickets (children) from chronic buffering of acidosis with bone mineral.
- Growth failure in paediatric patients.
- Proximal muscle weakness and fatigue.
- Urine pH persistently > 5.5 despite systemic acidosis.
Nephrolithiasis risk: Alkali therapy in Type 1 RTA should target a serum bicarbonate ≥ 22 mmol/L to reduce calcium phosphate supersaturation and prevent nephrolithiasis and nephrocalcinosis. Over-alkalinisation above 26 mmol/L is generally unnecessary and may increase calcium phosphate stone risk.
Type 2 RTA (Proximal) — HCO₃⁻ Wasting
Type 2 (proximal) RTA results from impaired reabsorption of filtered bicarbonate in the proximal convoluted tubule. Normally, approximately 85% of filtered HCO₃⁻ is reabsorbed proximally. When this mechanism fails, bicarbonate is lost in the urine, leading to NAGMA. The distal nephron retains intact H⁺-secretory capacity, so urine pH can acidify to < 5.5 once plasma bicarbonate falls below the reduced tubular threshold.
Aetiology
- Isolated proximal RTA: Rare; may be hereditary (SLC4A4/NBCe1 mutations, autosomal recessive).
- Generalised proximal tubular dysfunction (Fanconi syndrome): Accompanied by glycosuria, aminoaciduria, phosphaturia, uricosuria, and low-molecular-weight proteinuria.
- Causes of Fanconi syndrome: Tenofovir disoproxil fumarate, ifosfamide, cisplatin, aminoglycosides, valproate, expired tetracyclines, multiple myeloma (light-chain nephropathy), Wilson disease, cystinosis, hereditary fructose intolerance.
Clinical Features
- NAGMA with bicarbonaturia when plasma HCO₃⁻ is above the reduced threshold (typically 14–18 mmol/L).
- Hypokalaemia — exacerbated by alkali therapy, which increases distal sodium delivery and potassium secretion.
- Osteomalacia or rickets (especially in paediatric cases of cystinosis).
- Nephrolithiasis is less common than in Type 1 RTA.
- When Fanconi syndrome is present: glycosuria with normal blood glucose, phosphaturia with hypophosphataemia, aminoaciduria.
Potassium wasting: Alkali replacement in Type 2 RTA will worsen hypokalaemia by increasing distal HCO₃⁻ delivery and enhancing kaliuresis. Always co-prescribe potassium supplementation (e.g., slow-release KCl) and monitor serum K⁺ closely after initiation.
Type 4 RTA (Hyperkalaemic) — Aldosterone Deficiency
Type 4 RTA is the most common RTA encountered in clinical practice, particularly in patients with diabetic nephropathy or CKD. It results from either aldosterone deficiency or end-organ resistance to aldosterone in the principal cells of the cortical collecting duct, leading to impaired K⁺ secretion and reduced H⁺ secretion by the α-intercalated cells.
Aetiology
- Aldosterone deficiency: Diabetic nephropathy (hyporeninemic hypoaldosteronism — the most common cause), primary adrenal insufficiency, heparin / low-molecular-weight heparin therapy, NSAIDs, ACE inhibitors, ARBs.
- Aldosterone resistance: Obstructive uropathy, sickle cell nephropathy, pseudohypoaldosteronism type I (autosomal recessive ENaC mutations), amiloride, triamterene, trimethoprim, spironolactone, eplerenone, calcineurin inhibitors (ciclosporin, tacrolimus).
Clinical Features
- Mild NAGMA (HCO₃⁻ typically 18–22 mmol/L).
- Hyperkalaemia (K⁺ > 5.5 mmol/L) — the distinguishing feature.
- The degree of acidosis is often mild, and urine pH can be < 5.5 (distal H⁺ secretion is relatively intact; the primary defect is reduced ammoniagenesis due to hyperkalaemia).
- Often associated with CKD stage 3–4.
- Hypertension (volume expansion from sodium retention).
Hyperkalaemia management: Type 4 RTA may present with or precipitate life-threatening hyperkalaemia (K⁺ > 6.5 mmol/L). ECG changes (peaked T waves, widened QRS) require emergency management per local protocol before addressing the underlying RTA.
Pathophysiology
Normal renal acid–base handling involves three integrated mechanisms: proximal reabsorption of ~85% of filtered bicarbonate, distal secretion of H⁺ via H⁺-ATPase and H⁺/K⁺-ATPase, and renal ammoniagenesis (NH₃/NH₄⁺ production from glutamine in the proximal tubule). RTA arises when one or more of these processes are impaired.
| Feature | Type 1 (Distal) | Type 2 (Proximal) | Type 4 (Hyperkalaemic) |
|---|---|---|---|
| Primary defect | Impaired distal H⁺ secretion | Impaired proximal HCO₃⁻ reabsorption | Aldosterone deficiency/resistance |
| Serum HCO₃⁻ | Markedly low (12–20) | Low (14–18) | Mildly low (18–22) |
| Serum K⁺ | Low (hypokalaemia) | Low (hypokalaemia) | High (hyperkalaemia) |
| Urine pH during acidosis | > 5.5 (cannot acidify) | < 5.5 (can acidify below threshold) | < 5.5 (relatively preserved) |
| Nephrolithiasis risk | High | Low | Low |
| Alkali requirement | 1–2 mmol/kg/day | 4–10 mmol/kg/day | Low or none |
In Type 1 RTA, the primary defect results in inability to maximally acidify the urine. In Type 2 RTA, the distal nephron can secrete H⁺, but the excessive proximal bicarbonate loss exceeds distal capacity. In Type 4 RTA, hyperkalaemia itself suppresses proximal ammoniagenesis, contributing to impaired acid excretion — correcting the hyperkalaemia often resolves the acidosis.
Clinical Presentation & Diagnostic Criteria
When to Suspect RTA
- Normal anion gap metabolic acidosis in a patient with normal or near-normal GFR.
- Metabolic acidosis with hypokalaemia (Types 1 and 2) or hyperkalaemia (Type 4).
- Recurrent calcium phosphate kidney stones, particularly in younger patients.
- Osteomalacia or rickets with no clear vitamin D deficiency.
- NAGMA in the setting of Sjögren syndrome, SLE, or multiple myeloma.
- Failure to thrive or growth retardation in children.
Diagnostic Approach
The diagnostic algorithm begins with confirmation of NAGMA and proceeds through urine electrolytes, urine pH assessment, and specialised testing to differentiate RTA subtypes.
1
Confirm NAGMA
Serum HCO₃⁻ < 22 mmol/L, anion gap < 12. Venous blood gas to confirm pH < 7.35.
2
Check serum K⁺
Hypokalaemia → Type 1 or 2. Hyperkalaemia → Type 4.
3
Urine pH + urine electrolytes
Spot urine Na⁺, K⁺, Cl⁻, pH. Calculate urine anion gap (UAG = Na⁺ + K⁺ − Cl⁻).
4
Interpret UAG
Negative UAG (NH₄⁺ excretion intact) → non-RTA cause. Positive UAG → RTA likely.
5
Urine pH interpretation
Urine pH > 5.5 with acidosis → Type 1. Urine pH < 5.5 with acidosis + hypokalaemia → suspect Type 2 (test with bicarbonate loading). Urine pH < 5.5 + hyperkalaemia → Type 4.
6
Bicarbonate loading test (if Type 2 suspected)
IV NaHCO₃ infusion titrated to raise serum HCO₃⁻. Fractional HCO₃⁻ excretion > 15% confirms proximal RTA.
Urine osmolal gap (UOG): An alternative to UAG. UOG = measured urine osmolality − 2(Na⁺ + K⁺) − urea − glucose. A low UOG (< 150 mOsm/kg) in the setting of acidosis suggests impaired renal ammoniagenesis and supports RTA. UOG is preferred when urine pH is < 5.5.
Investigations
Essential
Serum electrolytes, urea, creatinine, eGFR
Confirm NAGMA pattern. Rule out CKD-associated uraemic acidosis. MBS item 66500.
Essential
Venous blood gas (VBG)
pH, pCO₂, HCO₃⁻, base excess. Arterial sampling rarely required. MBS item 66542.
Essential
Serum anion gap
Calculated as Na⁺ − (Cl⁻ + HCO₃⁻). Must be < 12 to classify as NAGMA. MBS item 66500.
Essential
Spot urine electrolytes (Na⁺, K⁺, Cl⁻) and urine pH
For UAG calculation. Urine pH must be measured on a fresh, mid-stream specimen. MBS item 69315.
Available
Serum aldosterone and renin (direct renin concentration)
To confirm hypoaldosteronism in Type 4 RTA. Ensure patient off ACEi/ARB/spironolactone ≥ 4 weeks if possible. MBS item 66845.
Available
Serum calcium, phosphate, alkaline phosphatase, 25-OH vitamin D
To assess for osteomalacia/renal osteodystrophy. MBS items 66512, 66583.
Available
Urinalysis for glucose, protein, amino acids
Screen for Fanconi syndrome. Glycosuria with normoglycaemia is a red flag. MBS item 69315.
Specialist
Bicarbonate loading / fractional excretion test
Requires IV NaHCO₃ infusion under nephrology supervision. Fractional HCO₃⁻ excretion > 15% confirms Type 2 RTA. Performed in tertiary centres only.
Specialist
Genetic testing (SLC4A1, ATP6V0A4, ATP6V1B1, SLC4A4)
Consider in paediatric patients or suspected hereditary RTA. Available through clinical genetics services and specialised laboratories (e.g., SA Pathology).
Available
Renal ultrasound
Screen for nephrocalcinosis (Type 1) and nephrolithiasis. MBS item 55300.
Available
Serum and urine protein electrophoresis
If multiple myeloma / light-chain disease suspected (especially in proximal RTA with Fanconi features). MBS item 69330.
Diagnosis & Treatment
Type 1 RTA — Treatment
The goal is to normalise serum bicarbonate (target ≥ 22 mmol/L), correct hypokalaemia, and prevent nephrolithiasis and osteomalacia.
Sodium Bicarbonate
Generic tablets · Oral alkali
Adult dose
1–2 mmol/kg/day PO in 2–4 divided doses (typical: 600 mg tablets, 2–4 tablets TDS). Titrate to serum HCO₃⁻ ≥ 22 mmol/L.
Paediatric dose
2–3 mmol/kg/day PO in divided doses.
Renal adjustment
No specific dose adjustment; monitor for fluid overload in CKD.
PBS status
✔ PBS General Benefit
Shohl's Solution (Citric Acid / Sodium Citrate)
Bicitra® · Oral alkali
Adult dose
15–30 mL PO TDS–QDS (1 mL provides ~1 mmol HCO₃⁻). Titrate to target HCO₃⁻.
Paediatric dose
2–5 mL/kg/day PO in divided doses.
Renal adjustment
Use with caution if eGFR < 30; increased citrate load.
PBS status
✔ PBS General Benefit
Potassium Chloride (slow-release)
Slow-K® · Potassium supplement
Adult dose
600–1200 mg (8–16 mmol K⁺) PO BD–TDS if serum K⁺ < 3.5 mmol/L. Monitor closely.
Paediatric dose
1–2 mmol/kg/day PO in divided doses.
Renal adjustment
Contraindicated if serum K⁺ > 5.0 mmol/L or severe CKD.
PBS status
✔ PBS General Benefit
Type 2 RTA — Treatment
Higher alkali doses are needed to replace proximal losses. Aggressive potassium supplementation is mandatory as alkali therapy worsens hypokalaemia.
Sodium Bicarbonate
Generic tablets · Oral alkali
Adult dose
4–10 mmol/kg/day PO in 4–6 divided doses. Often difficult to achieve target due to high dose requirements.
Paediatric dose
5–15 mmol/kg/day PO in divided doses.
Key note
Add potassium supplements concurrently. Monitor for abdominal distension and nausea at high doses.
PBS status
✔ PBS General Benefit
Thiazide Diuretic (adjunct)
Hydrochlorothiazide · Chloride depletion approach
Adult dose
Hydrochlorothiazide 12.5–25 mg PO daily. Causes mild volume contraction → enhances proximal HCO₃⁻ reabsorption → reduces alkali requirement.
Renal adjustment
Ineffective if eGFR < 15 mL/min.
PBS status
✔ PBS General Benefit
Tenofovir-associated proximal RTA: Patients on tenofovir disoproxil fumarate (TDF) who develop Fanconi syndrome should be switched to tenofovir alafenamide (TAF) or an alternative antiviral where possible. Monitor serum phosphate and urine glucose every 6 months in patients on long-term TDF.
Type 4 RTA — Treatment
Management targets the underlying cause of aldosterone deficiency/resistance and addresses hyperkalaemia.
Fludrocortisone
Florinef® · Mineralocorticoid replacement
Adult dose
0.1–0.3 mg PO daily. Start low (0.1 mg), titrate to K⁺ < 5.0 and HCO₃⁻ ≥ 22. Watch for fluid retention and hypertension.
Renal adjustment
Use cautiously in CKD; increased risk of fluid overload.
PBS status
✔ PBS General Benefit
Sodium Bicarbonate (low dose)
Generic tablets · If acidosis persists
Adult dose
600 mg (7.2 mmol) PO BD–TDS if HCO₃⁻ remains < 22 after fludrocortisone or if fludrocortisone is contraindicated.
PBS status
✔ PBS General Benefit
Sodium Zirconium Cyclosilicate (Lokelma®)
Lokelma® · Potassium binder (for hyperkalaemia)
Adult dose
10 g PO TDS for up to 48 h (acute), then 5–10 g PO daily (maintenance).
Renal adjustment
No dose adjustment required; effective across CKD stages.
PBS status
✘ Authority Required
Avoid nephrotoxic contributors: Discontinue or minimise NSAIDs, ACE inhibitors, ARBs, potassium-sparing diuretics, trimethoprim, and calcineurin inhibitors where clinically feasible, as these exacerbate hyperkalaemia in Type 4 RTA.
Monitoring
| Parameter | Frequency | Target |
|---|---|---|
| Serum bicarbonate | Every 1–2 weeks during titration; then every 3 months | 22–26 mmol/L |
| Serum potassium | Every 1–2 weeks initially; then every 3 months | 3.5–5.0 mmol/L |
| eGFR / serum creatinine | Every 3–6 months | Monitor for progression |
| Serum calcium, phosphate, ALP | Every 6 months | Normalise ALP; monitor bone health |
| Renal ultrasound | Annually in Type 1 RTA | Screen for nephrocalcinosis |
| Blood pressure | Every visit | < 130/80 mmHg |
| Urine calcium : creatinine ratio | Every 6 months (Type 1) | < 0.7 mmol/mmol |
Adjust alkali dosing based on serial bicarbonate levels. In patients on fludrocortisone, monitor for oedema, hypertension, and signs of volume overload. Paediatric patients require growth velocity monitoring at each visit.
Special Populations
Pregnancy
Sodium bicarbonate: Safe in pregnancy. Continue at pre-conception doses. Monitor serum bicarbonate more frequently (monthly) as pregnancy-related respiratory alkalosis may alter dose requirements.
Fludrocortisone: Category B3. May be continued if essential for mineralocorticoid replacement (e.g., Addison disease). Monitor for fluid retention and pre-eclampsia.
Thiazide diuretics: Generally avoided in pregnancy due to fetal risk; consider alternative approaches to reduce alkali requirement.
Sodium zirconium cyclosilicate: Insufficient safety data; avoid in pregnancy.
Paediatrics
Hereditary RTA: Type 1 with ATP6V1B1 mutations presents with sensorineural hearing loss — audiology screening is mandatory at diagnosis and annually.
Alkali dosing: Sodium bicarbonate 2–3 mmol/kg/day (Type 1) or 5–15 mmol/kg/day (Type 2) in divided doses. Use Shohl's solution if compliance is poor.
Growth monitoring: Serial height and weight percentiles every 3 months. Growth failure warrants re-evaluation of acidosis control.
Rickets screening: Serum calcium, phosphate, ALP, and wrist X-ray if clinically suspected.
Elderly
Type 4 predominance: Most common RTA subtype in older adults, particularly those with diabetic nephropathy and CKD.
Fludrocortisone caution: Increased risk of fluid overload, hypertension, and cardiac failure in the elderly. Start at 0.05 mg and titrate cautiously.
Polypharmacy review: Regularly audit medications contributing to hyperkalaemia (ACEi, ARBs, potassium-sparing diuretics, NSAIDs, trimethoprim).
Renal Impairment (CKD)
Distinguishing RTA from uraemic acidosis: RTA should be suspected when NAGMA is disproportionate to the degree of CKD (e.g., HCO₃⁻ < 18 in CKD stage 3).
Fludrocortisone: Fluid retention risk increases with declining GFR. Consider sodium bicarbonate alone if fludrocortisone is not tolerated.
Dialysis: Patients on haemodialysis may require adjusted dialysate bicarbonate; consult nephrology.
Hepatic Impairment
Sodium bicarbonate: No hepatic dose adjustment; however, assess for concurrent respiratory alkalosis in cirrhosis, which may mask acidosis severity.
Fludrocortisone: Use cautiously if portal hypertension/ascites present.
Immunocompromised
Drug-induced RTA: High prevalence of proximal RTA in patients on tenofovir (HIV), calcineurin inhibitors (transplant), and ifosfamide (oncology).
Amphotericin B: Causes both distal RTA and hypokalaemia. Monitor electrolytes every 48 h during IV amphotericin courses.
Screening: Consider routine bicarbonate and potassium monitoring in at-risk populations.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant. 2012;27(10):3691–3704.
- 2. Igarashi T, Sekine T, Inatomi J, Seki G. Unraveling the molecular pathogenesis of isolated proximal renal tubular acidosis. J Am Soc Nephrol. 2002;13(8):2171–2177.
- 3. Karet FE. Inherited distal renal tubular acidosis. J Am Soc Nephrol. 2002;13(8):2178–2184.
- 4. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160–2170.
- 5. Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012;27(12):4273–4287.
- 6. Rennke HG, Denker BM. Renal Pathophysiology: The Essentials. 5th ed. Philadelphia: Wolters Kluwer; 2021.
- 7. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Australian facts. Cat. no. PHE 229. Canberra: AIHW; 2023.
- 8. Royal Australian College of General Practitioners (RACGP). National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. 4th ed. East Melbourne: RACGP; 2024.
- 9. RHDAustralia. Australian guidelines for best practice in the diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: RHDAustralia; 2020.
- 10. The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and Kidney Health Australia. Caring for Australasians and New Zealanders with kidney disease. Melbourne: Kidney Health Australia; 2020.
- 11. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011;7(2):75–84.
- 12. American Society of Nephrology. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int. 2024;105(4S):S117–S314.